文献速递系统性红斑狼疮其他结缔组织病自身炎症与 IgG4 相关病

SOCS1功能不全个体的临床表现、疾病外显率与治疗:一项基于注册登记和人群的研究

Clinical manifestations, disease penetrance, and treatment in individuals with SOCS1 insufficiency: a registry-based and population-based study.
PubMed 文献 · Lancet Rheumatol · 2025-02-27

该研究利用欧洲免疫缺陷学会(ESID)注册登记和英国生物银行两个独立队列,纳入119例SOCS1功能不全个体,描述其临床表现、疾病轨迹和外显率,并评估JAK抑制剂疗效。ESID队列67例中62例(93%)有症状,过敏、炎症性胃肠道和皮肤表现、自身免疫性血细胞减少及淋巴增殖最常见,风湿学表现占37%;JAK抑制剂在13例中12例(92%)显示良好结果。

要点

  • SOCS1功能不全以频繁的过敏和风湿学表现为特征,区别于其他遗传性自身免疫性淋巴增殖性疾病。
  • 疾病外显率不完全,且女性高于男性。
  • JAK抑制剂是SOCS1功能不全有前景的靶向治疗。

核心结论

  • SOCS1功能不全因频繁的过敏和风湿学表现而不同于其他遗传性自身免疫性淋巴增殖性疾病。
  • 外显率不完全,且女性高于男性。
  • JAK抑制剂是SOCS1功能不全患者有前景的靶向治疗。

研究设计与样本

  • 本研究使用两个独立队列的数据:欧洲免疫缺陷学会(ESID)注册登记和英国生物银行。
  • ESID注册登记参与者来自九个欧洲国家(奥地利、比利时、法国、德国、爱尔兰、意大利、葡萄牙、瑞典和乌克兰)、中国、台湾和美国,纳入标准为具有杂合、功能验证的SOCS1变异。
  • 英国生物银行参与者纳入标准为携带ESID注册登记队列中检测到的任何SOCS1变异或任何其他被归类为高影响的SOCS1变异。
  • ESID注册登记参与者在当地实验室检测相关自身抗体,JAK抑制剂治疗反应由治疗医师使用视觉模拟量表评估。
  • 分析采用描述性统计;有生活经验的人未参与研究设计。

主要发现

  • 共纳入119例SOCS1功能不全参与者:ESID注册登记67例(2021年2月15日至2023年12月31日入组),英国生物银行52例。
  • ESID注册登记67例中,女性39例(58%),男性28例(42%),中位年龄28岁(IQR 15-44,范围2-85);鉴定出27种不同的单等位基因SOCS1变异。
  • ESID注册登记67例中62例(93%)有症状,5例(7%)为无症状家庭成员;62例有症状者中,过敏33例(50%)、炎症性胃肠道表现22例(36%)、皮肤表现18例(29%)、自身免疫性血细胞减少24例(39%)、淋巴增殖23例(37%)最为常见。
  • 风湿学表现23例(37%),包括系统性红斑狼疮、舍格伦病和类风湿关节炎,具有典型自身抗体谱;62例有症状者中42例(68%)至少有三种不同表现。
  • 英国生物银行发现52例携带高影响SOCS1变异参与者,女性29例(56%),男性23例(44%),中位年龄72岁(65-78,57-86);仅30例(58%)出现了可能与SOCS1功能不全相关的表现;过敏和风湿学表现在英国生物银行参与者中比ESID注册登记更常见;英国生物银行有症状参与者中女性21例(70%)、男性9例(30%)。

关键数值与推荐

  • ESID注册登记纳入标准:杂合、功能验证的SOCS1变异。
  • 英国生物银行纳入标准:ESID注册登记队列中检测到的任何SOCS1变异或任何其他被归类为高影响的SOCS1变异。
  • 临床表现归纳为九个亚组,英国生物银行参与者收集ICD-10诊断代码。
  • JAK抑制剂治疗反应由治疗医师使用视觉模拟量表评估。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Suppressor of cytokine signalling 1 (SOCS1) insufficiency is an inborn error of immunity affecting the negative regulation of cytokine and growth factor signalling. We aimed to enhance the understanding of clinical manifestations, disease trajectories, disease penetrance, and the effect of Janus kinase (JAK) inhibition in individuals with SOCS1 insufficiency. METHODS: This study used data from two independent cohorts: the European Society for Immunodeficiencies (ESID) registry and the UK Biobank. Participants from the ESID registry were from nine European countries (Austria, Belgium, France, Germany, Ireland, Italy, Portugal, Sweden, and Ukraine), China, Taiwan, and the USA. Participants from the ESID registry were eligible if they had heterozygous, functionally validated SOCS1 variants; participants from the UK Biobank were included if they had any SOCS1 variant detected in the ESID registry cohort or any other SOCS1 variant that was classed as high-impact. Clinical manifestations of the underlying SOCS1 insufficiency were documented and summarised into nine subgroups, with ICD-10 diagnosis codes collected for participants from the UK Biobank. Participants from the ESID registry were tested for relevant autoantibodies in their local laboratory. Responses to JAK inhibitor treatment in participants from the ESID registry were assessed by the treating physician using a visual analogue scale. Descriptive statistics were used for analysis. People with lived experience were not involved in the study design. FINDINGS: We included 119 participants with SOCS1 insufficiency: 67 from the ESID registry, enrolled between Feb 15, 2021, and Dec 31, 2023, and 52 from the UK Biobank. Of the 67 participants from the ESID registry, 39 (58%) were female, 28 (42%) were male, and the median age was 28 years (IQR 15-44, range 2-85). 27 different monoallelic SOCS1 variants were identified in these participants. 62 (93%) of the 67 participants in the ESID registry cohort were symptomatic and five (7%) were asymptomatic family members; of the 62 participants with symptoms, allergy (33 [50%]), inflammatory gastrointestinal (22 [36%]) and skin (18 [29%]) manifestations, autoimmune cytopenia (24 [39%]), and lymphoproliferation (23 [37%]) were most frequent. Rheumatological manifestations (23 [37%]) included systemic lupus erythematosus, Sjögren's disease, and rheumatoid arthritis, with typical autoantibody profiles. 42 (68%) of the 62 symptomatic participants had at least three different manifestations. In the UK Biobank we found 52 participants carrying high-impact SOCS1 variants; 29 (56%) were female, 23 (44%) were male, and the median age was 72 years (65-78, 57-86). Only 30 (58%) of these participants had developed manifestations that were potentially related to SOCS1 insufficiency. Allergy and rheumatological manifestations were more common in participants from the UK Biobank than the ESID registry. Female predominance (21 [70%] of 30 participants were female and nine [30%] were male) was also found among symptomatic participants from the UK Biobank. Treatment with JAK inhibitors showed promising results in 12 (92%) of 13 participants in the ESID registry. INTERPRETATION: SOCS1 insufficiency differs from other genetic autoimmune lymphoproliferative disorders by the presence of frequent atopic and rheumatological manifestations. Penetrance is incomplete and is higher in females than in males. JAK inhibition is a promising targeted therapy for patients with SOCS1 insufficiency. FUNDING: German Research Foundation (DFG).

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Hadjadj J, Wolfers A, Borisov O, et al. Clinical manifestations, disease penetrance, and treatment in individuals with SOCS1 insufficiency: a registry-based and population-based study. Lancet Rheumatol. 2025. PMID: 40024253. doi:10.1016/S2665-9913(24)00348-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。